Global mAb Biosimilars Market 2016-2020

Publisher Name :
Date: 23-Sep-2016
No. of pages: 103
Inquire Before Buying

Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.

The analysts forecast spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of more than 57% during the period 2015-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.

The market is divided into the following segments based on geography:


  • Europe

  • Asia

  • ROW


The report, Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • Biocon

  • Celltrion

  • Dr. Reddy's Laboratories

  • Hospira


Other prominent vendors


  • 3SBio

  • Accord Healthcare

  • AET Biotech

  • Allergan

  • Alvartis Pharma

  • Amega Biotech

  • Amgen

  • Apotex

  • Aspen

  • AstraZeneca

  • Aurobindo Pharma

  • Baxter

  • Bharat Serums

  • Bio Sidus

  • Biogen

  • Bionovis

  • Bioton

  • BioXpress Therapeutics

  • Boehringer Ingelheim

  • Boston Oncology

  • Cipla

  • Coherus Biosciences

  • Daiichi Sankyo

  • Emcure Pharmaceuticals

  • Gedeon Richter

  • GeneScience Pharmaceuticals

  • GSK

  • Hetero Drugs

  • iBio

  • Intas Pharmaceuticals

  • JCR Pharmaceuticals

  • LG Lifesciences

  • Lonza

  • Merck

  • Mitsubishi Tanabe Pharma

  • Momenta Pharmaceuticals

  • Mylan

  • Natco Pharma

  • Novartis

  • Pfenex

  • Pfizer

  • Ranbaxy Laboratories

  • Roche Holding

  • Samsung Biologics

  • Sanofi

  • Synthon


Market driver


  • •Rise in number of patent expiries

  • For a full, detailed list, view our report


Market challenge


  • Physicians' reluctance to prescribe biosimilars

  • For a full, detailed list, view our report


Market trend


  • Emergence of biosimilars

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global mAb Biosimilars Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights
Biosimilars: Overview
Comparative analysis of generic small molecules and biosimilars
Biosimilars market opportunities
Challenges for new entrants
Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Five forces analysis

PART 07: Market segmentation by application
Global chronic and autoimmune diseases mAb biosimilars market
Global oncology mAb biosimilars market

PART 08: Geographical segmentation
Global mAb biosimilars market by geographical segmentation 2015-2020
mAb biosimilars market in Europe
mAb biosimilars market in Asia
mAb biosimilars market in rest of the world

PART 09: Market drivers
Rise in number of patent expiries
Need for cost-effective treatment
Reimbursement benefits for biosimilars
Favorable government regulations

PART 10: Impact of drivers

PART 11: Market challenges
Physicians' reluctance to prescribe biosimilars
Multiple manufacturing complexities
Risks related to drug failure
Limited availability of biosimilar products
Difficulties in patient recruitment for clinical trials

PART 12: Impact of drivers and challenges

PART 13: Market trends
Emergence of biosimilars
Outsourcing of manufacturing activities
Need for high investment in R&D
High growth in the emerging markets
Rising number of strategic collaborations

PART 14: Vendor landscape
Competitive scenario

PART 15: Key vendor analysis
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
Other prominent vendors

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Global mAb biosimilars market: Snapshot
Exhibit 03: Global mAb biosimilars market: Growth analysis
Exhibit 04: Global mAb biosimilars market: Key buying criteria 2015
Exhibit 05: Global mAb biosimilars market: Timeline 2014-2020
Exhibit 06: Global mAb biosimilars market: Impact of key customer segments 2015
Exhibit 07: Definition of biosimilars by agencies
Exhibit 08: Comparison between generic small molecules and biosimilars
Exhibit 09: Impact of biosimilars cost savings on different sectors
Exhibit 10: Factors affecting success of biosimilars
Exhibit 11: Biosimilars industry: Point-of-view
Exhibit 12: Factors influencing uptake of biosimilars
Exhibit 13: Global mAb biosimilars market: Strategic factors for new market entrants
Exhibit 14: Challenges for new entrants
Exhibit 15: Bio-betters and its impact on market
Exhibit 16: Global mAb biosimilars market: Pipeline snapshot 2015
Exhibit 17: Pipeline portfolio: Global mAb biosimilars market 2015
Exhibit 18: Patent expiry in key mAb biosimilars markets 2000-2020
Exhibit 19: Global mAb biosimilars market: Developed and emerging markets 2015
Exhibit 20: Global mAb biosimilars market 2015-2020 ($ millions)
Exhibit 21: Biosimilars: Savings potential in five European countries and US ($ billions) 2016-2020
Exhibit 22: Global spending on mAb biosimilars 2010-2020 ($ billions)
Exhibit 23: Global mAb biosimilars market: Key metrics analysis snapshot
Exhibit 24: Current and future trends in global mAb biosimilars market
Exhibit 25: Factors influencing the global mAb biosimilars market 2015
Exhibit 26: Five forces analysis
Exhibit 27: Global mAb biosimilars market: Segmentation by application (2015-2020)
Exhibit 28: Applications of mAb biosimilars and its impact on growth of market
Exhibit 29: Global mAb biosimilars market segmentation: Growth cycle analysis
Exhibit 30: Population aged 60 years and over (millions)
Exhibit 31: Global chronic and autoimmune diseases mAb biosimilars market 2015-2020 ($ millions)
Exhibit 32: Opportunity analysis of chronic and autoimmune diseases mAb biosimilars market by application
Exhibit 33: Global incidence of cancer 2015-2020 (millions)
Exhibit 34: Global oncology mAb biosimilars market 2015-2020 ($ millions)
Exhibit 35: Opportunity analysis of global oncology mAb biosimilars market by type of application
Exhibit 36: Global mAb biosimilars market segmentation by application 2015
Exhibit 37: Global mAb biosimilars market by geography: Outlook 2015-2020
Exhibit 38: Global mAb biosimilars market by geography 2015
Exhibit 39: Market penetration of originators and biosimilars by region/country
Exhibit 40: Global mAb biosimilars market landscape: Country analysis
Exhibit 41: mAb biosimilars market in Europe: Opportunity analysis
Exhibit 42: mAb biosimilars market in Europe 2015-2020 ($ millions)
Exhibit 43: PEST analysis: mAb biosimilars market in Europe 2015
Exhibit 44: mAb biosimilars market in Asia: Opportunity analysis
Exhibit 45: mAb biosimilars market in Asia 2015-2020 ($ millions)
Exhibit 46: PEST analysis: mAb biosimilars market in Asia 2015
Exhibit 47: mAb biosimilars market in rest of the world: Opportunity analysis
Exhibit 48: mAb biosimilars market in rest of the world 2015-2020 ($ millions)
Exhibit 49: Benefits of mAb biosimilars to US healthcare system
Exhibit 50: PEST analysis: mAb biosimilars market in rest of the world 2015
Exhibit 51: Impact of drivers and challenges on global mAb biosimilars market
Exhibit 52: Patent analysis of mAb in the US
Exhibit 53: Patent analysis of biologicals in Europe
Exhibit 54: Impact of drivers
Exhibit 55: Physicians' reluctance to prescribe biosimilars: Key reasons
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Global mAb biosimilars market: Impact assessment of key trends
Exhibit 58: Competitive assessment of vendors
Exhibit 59: Key vendors: Geographical presence 2015
Exhibit 60: Major vendors in global mAb biosimilars market: Mergers, acquisitions, and partnerships
Exhibit 61: Biocon profile
Exhibit 62: Biocon: Metrics analysis
Exhibit 63: Biocon growth strategy matrix
Exhibit 64: Biocon: Opportunity assessment
Exhibit 65: Celltrion profile
Exhibit 66: Celltrion: Metrics analysis
Exhibit 67: Celltrion growth strategy matrix
Exhibit 68: Celltrion: opportunity assessment
Exhibit 69: Dr. Reddy's Laboratories profile
Exhibit 70: Dr. Reddy's Laboratories: Metrics analysis
Exhibit 71: Dr. Reddy's Laboratories growth strategy matrix
Exhibit 72: Dr. Reddy's Laboratories Opportunity assessment
Exhibit 73: Hospira profile
Exhibit 74: Hospira: Metrics analysis
Exhibit 75: Hospira growth strategy matrix
Exhibit 76: Hospira opportunity growth assessment

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design
    Published: 01-Mar-2017        Price: US 2995 Onwards        Pages: 117
    Summary Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. A biosimilar is a bio-therapeutic that is clinically highly similar to an approved innovative product (reference product) in terms of active ingredients, and has no meaningful differences in efficacy and safety. The complexities of manufacturing a biological drug also apply to b......
  • Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017
    Published: 01-Mar-2017        Price: US 1450 Onwards        Pages: 79
    DelveInsight's, "Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epide......
  • Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021
    Published: 05-Jan-2017        Price: US 5650 Onwards        Pages: 152
    The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region. On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest s......
  • 2017-2022 Global Top Countries Biologics and Biosimilars Market Report
    Published: 07-Dec-2016        Price: US 4960 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Biologics and Biosimilars in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Roche - Amgen - AbbVie - Sanofi-Aventis - Johnson & Johnson......
  • Global Biologics and Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 3480 Onwards        Pages: 110
    A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured ......
  • Europe Adalimumab Biosimilar Market Report 2016
    Published: 23-Nov-2016        Price: US 3900 Onwards        Pages: 119
    Notes: Sales, means the sales volume of Adalimumab Biosimilar Revenue, means the sales value of Adalimumab Biosimilar This report studies sales (consumption) of Adalimumab Biosimilar in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - AET BioTech - Amgen - Boehringer Ingelheim......
  • United States Adalimumab Biosimilar Market Report 2016
    Published: 16-Nov-2016        Price: US 3800 Onwards        Pages: 111
    Notes: Sales, means the sales volume of Adalimumab Biosimilar Revenue, means the sales value of Adalimumab Biosimilar This report studies sales (consumption) of Adalimumab Biosimilar in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AET BioTech - Amgen - Boehringer Ingelheim - Coherus Biosciences - Fujifilm Kyowa Kirin Biologics - LG Life Sciences/Moch......
  • Japan Biosimilar Monoclonal Antibodies Market Report 2016
    Published: 14-Nov-2016        Price: US 3400 Onwards        Pages: 119
    Notes: Sales, means the sales volume of Biosimilar Monoclonal Antibodies Revenue, means the sales value of Biosimilar Monoclonal Antibodies This report studies sales (consumption) of Biosimilar Monoclonal Antibodies in Japan market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Celltrion - Boehringer Ingelheim - Dr Reddy's - Sandoz - Zydus - Samsung - Amgen -......
  • Japan Biosimilars Market Report 2016
    Published: 14-Nov-2016        Price: US 3400 Onwards        Pages: 122
    Notes: Sales, means the sales volume of Biosimilars Revenue, means the sales value of Biosimilars This report studies sales (consumption) of Biosimilars in Japan market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Roche - Amgen - AbbVie - Sanofi-Aventis - Johnson & Johnson - Pfizer - Novo Nordisk - Eli Lilly - Novartis - Merck - 3sbio......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs